Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | POLB | P06746 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8824794 | 0.92 | ALDH1A1 (1.00) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL9468747 | 0.90 | KMT2A (0.82) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL14192656 | 0.90 | KMT2A (0.82) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL12300221 | 0.90 | MEN1 (0.82) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL7931375 | 0.89 | KMT2A (0.80) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL2374142 | 0.89 | MEN1 (0.80) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL13329336 | 0.89 | KMT2A (0.80) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL10604241 | 0.89 | MEN1 (0.80) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL30662094 | 0.88 | MEN1 (0.78) | MEN1KMT2AALDH1A1SMN1; SMN2POLB | |
| SCHEMBL22693560 | 0.86 | KMT2A (0.76) | MEN1KMT2AALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398680-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-09-03 | — | — | US | disclosed |
| US-10398749-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-09-03 | — | — | US | disclosed |
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | Board of Regents of the Nevada System of Higher Education, on behalf of the Univ of Nevada, Reno (US) | 2019-08-08 | — | — | US | disclosed |
| US-10272069-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-04-30 | — | — | US | disclosed |
| US-10206903-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2019-02-19 | — | — | US | disclosed |
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028992-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2892525-B1 | METHODS OF TREATING MUSCULAR DYSTROPHY | UNIV NEVADA RENO (US) | 2018-06-13 | — | — | EP | disclosed |
| US-9980943-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEMS OF HIGHER EDUCATION ON BEHALF OF THE NEVADA, RENO (US) | 2018-05-29 | — | — | US | disclosed |
| US-9980943-B2 | Methods of treating muscular dystrophy | BOARD OF REGENTS OF THE NEVADA SYSTEMS OF HIGHER EDUCATION ON BEHALF OF THE NEVADA, RENO (US) | 2018-05-29 | — | — | US | disclosed |
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY | 2015-10-15 | — | — | US | disclosed |
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSITY | 2015-10-15 | — | — | US | disclosed |
| WO-2014040077-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION, ON BEHALF OF THE UNIVERSISITY OF NEVADA, RENO (US) | 2014-03-13 | — | — | WO | disclosed |
| US-20140072536-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072536-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA (US) | 2014-03-13 | — | — | US | disclosed |
| US-7964625-B2 | Antibiotics comprising bis(1-aryl-5-tetrazoly1)methane derivatives | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2011-06-21 | — | — | US | disclosed |
| EP-1937257-B1 | NOVEL ANTIBIOTICS COMPRISING BIS(1-ARYL-5-TETRAZ0LYL)METHANE DERIVATIVES | TNO (NL) | 2010-12-08 | — | — | EP | disclosed |
| US-20080280964-A1 | Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2008-11-13 | — | — | US | disclosed |
| EP-1937257-A1 | NOVEL ANTIBIOTICS COMPRISING BIS(1-ARYL-5-TETRAZ0LYL)METHANE DERIVATIVES | Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO (NL) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007037685-A1 | NOVEL ANTIBIOTICS COMPRISING BIS(1-ARYL-5-TETRAZ0LYL)METHANE DERIVATIVES | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290276-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | MEN1 4859/4885KMT2A 3360/4885ALDH1A1 342/4885 |
| US-10272069-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | MEN1 4859/4885KMT2A 3360/4885ALDH1A1 342/4885 |
| US-10028992-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | MEN1 4859/4885KMT2A 3360/4885ALDH1A1 342/4885 |
| US-10398680-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | MEN1 4859/4885KMT2A 3360/4885ALDH1A1 342/4885 |
| US-10398749-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | MEN1 4859/4885KMT2A 3360/4885ALDH1A1 342/4885 |
| US-20190240195-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | MEN1 4859/4885KMT2A 3360/4885ALDH1A1 342/4885 |
| US-10206903-B2 | Methods of treating muscular dystrophy | ITGB7, ITGA2B, ITGB1 | MEN1 4859/4885KMT2A 3360/4885ALDH1A1 342/4885 |
| US-20140072536-A1 | METHODS OF TREATING MUSCULAR DYSTROPHY | ITGB7, ITGA2B, ITGB1 | MEN1 4859/4885KMT2A 3360/4885ALDH1A1 342/4885 |
| US-20080280964-A1 | Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives | LAS1L, AAAS, RPS5 | MEN1 1009/4885KMT2A 2575/4885ALDH1A1 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.